

Prevalence and genotype of human papillomavirus in laryngeal cancer patients

Abstract

Introduction: Squamous cell cancer (¹ SCC) of the larynx is the most common type of cancer. Human papillomavirus (²HPV) is an etiological agent for head and neck cancers, especially laryngeal cancer. It is necessary to increase our knowledge about the role of HPV in the cause of laryngeal SCC, its prevalence in each geographic region, and its high-risk types in order to facilitate the development of new, specific and more targeted methods.

Objective: The present study was conducted to investigate the prevalence and genotype of human papillomavirus in laryngeal cancer patients.

Materials and Methods: The current research is a cross-sectional descriptive study. Patients were included in the study by census method. Sampling from the pathology department and medical records using patient files and samples of Laryngeal cancer referred to the medical education centers of Mazandaran University of Medical Sciences. Statistical analyzes were performed with the help of SPSS26 software.

Results: The findings of this study indicate that 14.5% of patients were HPV+ and the prevalence of high-risk genomes is type 18 (30.7%), type 31 (7.6%), type 33 (23%), and type 6 (36.3%). Also, genomes 6, 18, and 33 were the most common.

Conclusion: It can be stated that the role of human papillomavirus in the etiology of precancerous lesions of the larynx and laryngeal cancer is undeniable and due to its distinct clinical behavior in terms of high-risk types in each geographical region.

Keywords: Laryngeal cancer, human papillomavirus, genotype, prevalence

Mehdi Nikkhah¹, Mojtaba Hajihoseini^{2*}, Rostam Pourmoussa³, Maryam Ghasemi⁴

1. Department of Otorhinolaryngology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

2. Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

E-mail:

dr.mojtabahajihoseini@gmail.com
/Contact number: 09371138192

3. Department of Otolaryngology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

4. Department of Pathology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

Introduction

Laryngeal cancer is the uncontrolled growth of malignant cells in the larynx and its surrounding tissues. Laryngeal cancer is the 20th most common human cancer (1). Every year, 151,000 new cases are diagnosed worldwide and 88,000 deaths are related to it (2). Squamous cell cancer (SCC1) of the larynx is the most common cancer among head and neck cancers, which accounts for about 60% of all cancers. forms the neck (3). Like most head and neck cancers, squamous cell cancer is associated with a history of smoking <excessive alcohol consumption >improper diet <synonyms of gastroesophageal reflux disease (GERD) and laryngopharyngeal reflux (LPR) (4,5). Virus Human papillomaviruses (HPV2) are viruses with a circular double-stranded DNA genome >8000 nucleotides that can cause tumors (6). And it is an etiological factor for head and neck cancers, especially in laryngeal cancer, and it is known to be an important carcinogenic factor (7, 8). Various studies have shown the relationship between human papillomavirus infection and the process of cancer. The most common parts of the body that are attacked by the virus include the reproductive system, skin, as well as pharynx, mouth, and larynx (9). The epithelium of the larynx is sensitive to HPV infection. HPV penetrates the organ through micro-damage to the mucous membrane, which allows it to access the basal layer of the epithelium. The virus infects the absorbing and dividing cells. HPV attaches itself to the cell membrane using epidermal

growth factor receptors and infects the cells in this way (10, 11). Today, more than 150 types of HPV genomes are known, which are divided into high-risk and low-risk categories based on their carcinogenic power (12). The role of human papilloma (HPV) DNA in head and neck cancer and its relationship with other risk factors have been widely investigated (13, 14). Worldwide, approximately 38,000 cases of head and neck squamous cell cancer are related to HPV (15). Studies of HPV infection in laryngeal SCC have reported a wide range of results. Some studies have reported a prevalence of 0% -80% (16) and some 20-30% (17), which may be due to the use of different techniques with different sensitivities and different sampling methods (biopsy or scraping, fixation formalin, and paraffin freezing or tissue freezing) (18). The most common diagnostic methods used include polymerase chain reaction (PCR), in situ hybridization (ISH), and immunohistochemistry (³IHC) (19). The best diagnostic method is to determine the presence of HPV DNA in tumor tissue samples by PCR and ISH methods. A combination of these two approaches detects HPV infection more reliably than each of these methods with a sensitivity of 97% and a specificity of 94% (20). On the other hand, studies have shown that the prevalence of HPV in LSCC can be different in terms of geography and ethnic groups, and this can be due to genetic diversity or environmental and cultural differences (8, 21). In a meta-analysis study, Kramer et al paid special attention to the geographical location of the

¹Squamous cell carcinoma

²Human Papilloma Virus

studies conducted on the relationship between HPV infection and head and neck cancer, especially laryngeal cancer, and confirmed that the prevalence of HPV infection in head and neck cancer cases depends on the geographical area where the patients are. It depends. The prevalence of HPV in laryngeal infection is higher in Asia and accounts for 38.2% of squamous cell cancers (22). Laryngeal cancer associated with viral infections has a long course of progression resulting from a persistent and latent infection. Meanwhile, other HPV-related head and neck cancers have less severe disease periods, respond better to radiation therapy and chemotherapy, and lead to long-term patient survival (23, 24). Currently, the main factor of clinical prognosis in these patients is determined by the spread of the tumor(25) and the knowledge about how to better respond to the treatment of patients with HPV related to laryngeal cancer and its importance in the prognosis of patients is weak, and more research on It is needed on this topic (26). Since there are 2 types of preventive vaccines against the HPV virus, bivalent (HPV 16 and HPV18) and quadrivalent (against HPV 16, 18, 11, and 6) are available and the vaccines are designed to induce the production of antibodies against the viral protein. and do not have viral DNA(26), as a result, knowing the high-risk types of this virus in any society can be effective in choosing the correct type of vaccine to prevent infection in the at-risk group. The role of human papillomavirus in the etiology of precancerous lesions of the larynx and laryngeal cancer. It is undeniable and due to its distinctive clinical behavior in terms of high-risk types in each geographical region, it is a subject that has a lot of scope for research. It is necessary to increase our knowledge about the role of HPV in the cause of laryngeal SCC, its prevalence in each geographic region, and its high-risk types in an attempt to the prevalence and genotype of human papillomavirus in cancer patients. Laryngology was performed in hospitals affiliated with Mazandaran University of Medical Sciences. Facilitate the development of new, specific, and more agreed methods and to identify and plan more features of each tumor. For more specific treatment. As a result, according to the search of available sources and databases, extensive evidence was not found regarding the prevalence and high-risk types of human papillomavirus in laryngeal cancer patients in the hospitals of the country, the present study aims to investigate

Materials and Methods:

This present research is a cross-sectional descriptive study that was conducted in the form of data extraction using a checklist from the files of laryngeal cancer patients referred to hospitals affiliated with Mazandaran University of Medical Sciences during the years 2018-2021. Patients were included in the study by census method. To collect data, the researcher's checklist and the patient's pathology sample were used.

Sampling from the pathology department and medical records using patient files and samples Laryngeal cancer referred to the medical education centers of Mazandaran University of Medical Sciences was investigated and patients' information was checked and forms were completed, and the samples in the pathology department were used to perform PCR and then determine the genotype. The informed consent form for entering the study was completed for all participants and then statistical analyzes were performed with the help of SPSS26 software.

Results:

During the 3-year study period from September 2018 to August 2021, 90 patients were examined by the pathology department and their information was entered within the specified period. In this study the most cases were men (92.5%). Mean and standard deviation of age at patients was 62.30±11.85 years, with the youngest and the oldest patients as 35 years and 88 years, respectively. Also 55.6% of the patients had a history of alcohol consumption. The stage of cancer in most patients was in stage 1A,67 (74.4%). (Table 1)

Based on the results of the study, 13 patients' secretions were PCR positive for the HPV virus, and in 77 people of patients, PCR was negative, which includes 14.5% and 85.5% of patients, respectively.

The findings of this study indicate that 14.5% of patients were HPV+ and the high-risk genomes is type 18 was the most case. (Table 2)

Table 1: The cancer stage of patients

Stage of cancer	N	%
1A	1	1.1
2A	67	74.4
2B	4	4.4
3A	3	3.3
4A	15	16.7

Table 2: Virus genotype of patients

Virus Genotype	N	%
6	5	38.4
18	4	30.7
31	1	7.6
3	3	23

Discussion and conclusion:

squamous cell cancer of the larynx is the most common type of cancer of the head and neck, which accounts for about 60% of It forms head and neck cancers (3). Various studies have shown the relationship between human papillomavirus infection and the process of cancer. The most common parts of the body that are attacked by the virus include the reproductive system, skin, as well as pharynx, mouth, and larynx (9). Today, more than 150 types of HPV genomes are known, which are divided into high-risk and low-risk categories based on their carcinogenic power (12). Studies have reported the prevalence of HPV infection in laryngeal SCC with a wide range of results. Some studies have reported a prevalence of 0% -80% (16) and some 20-30% (17), which may be due to the use of different techniques with different sensitivities and different sampling methods (biopsy or scraping, fixation formalin, and paraffin freezing or tissue freezing) (18). The best diagnostic method is to determine the presence of HPV DNA in tumor tissue samples by PCR and ISH methods. On the other hand, studies have shown that the prevalence of HPV in LSCC can be different in terms of geography and ethnic groups, and this can be due to genetic diversity or environmental and cultural differences (8, 21). In a meta-analysis study, Kramer et al paid special attention to the geographical location of the studies conducted on the relationship between HPV infection and head and neck cancer, especially laryngeal cancer, and confirmed that the prevalence of HPV infection in head and neck cancer cases depends on the geographical area where the patients are. It depends. The prevalence of HPV in laryngeal infection is higher in Asia and accounts for 38.2% of squamous cell cancers (22). Currently, the main factor of clinical prognosis in these patients is determined by the spread of the tumor(25) and the knowledge about how to better respond to the treatment of patients with HPV related to laryngeal cancer and its importance in the prognosis of patients is weak, and more research on this issue is needed (26). Since there are 2 types of preventive vaccines against the HPV virus, bivalent (HPV 16 and HPV18) and quadrivalent (against HPV 16, 18, 11, and 6) are available and vaccines for They are designed to induce antibody production against viral protein and do not contain viral DNA (26), as a result, knowing the high-risk types of this virus in any society can be effective in choosing the correct type of vaccine to prevent infection in the at-risk group. The role of human papillomavirus in the etiology of precancerous lesions of the larynx and laryngeal cancer is undeniable, and due to its distinct clinical behavior in terms of high-risk types in each geographical region, it is a subject that has a lot of scope for research. It is necessary to increase our knowledge about the role of HPV in the cause of laryngeal SCC, its prevalence in each geographic region, and its high-risk types in order to facilitate the development of new, specific, and

more targeted methods and to identify and plan more features of each tumor. For more specific treatment. Therefore, considering the importance of the mentioned cases, this study was conducted to investigate the prevalence and genotype of human papillomavirus in laryngeal cancer patients referred to hospitals affiliated with Mazandaran University of Medical Sciences. The findings of this study indicate that 13 patients were HPV+ and 77 patients were HPV-, which includes 14.5% and 85.5% of patients, respectively. Also, based on the results of the prevalence of high-risk genomes, type 18 in 4 cases, type 31 in 1 case, type 33 in 3 cases, and type 6 genome in 5 cases, which include 30.7%, 7.6%, 23% and 38.4% of the positive cases, respectively. Thus, genomes 6, 18, and 33 were the most common in Mazandarani patients of the study population.

Suggestions:

conducting a more comprehensive study with higher sample size and by different experts,
conducting a systematic review and meta-analysis in the scope of the present study, and giving a
on vaccination to prevent infection in the at-risk group with a quadrivalent vaccine (against HPV 16, 18, 11, and 6) after further studies and investigation, conducting more
studies that the diagnostic method used in their study is a combination of PCR and ISH methods and therefore has a higher and more reliable diagnostic capability than a specific method.

Acknowledgments

This paper was sponsored by the Department of Research & Technology at Mazandaran University of Medical Sciences, Sari, Iran. We would like to thank this Department and nursing staff who participated in this research project.

References:

1. Devita Jr VT, Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg's cancer: principles & practice of oncology: Lippincott Williams & Wilkins; 2015.
2. Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre M, et al. Global Burden of Disease Cancer Collaboration The Global Burden of Cancer 2015; 1: 505–27. *JAMA Oncol.*; 2013.
3. Rodrigo JP, García-Carracedo D, González MV, Mancebo G, Fresno MF, García-Pedrero J. Podoplanin expression in the development and progression of laryngeal squamous cell carcinomas. *Molecular cancer.* 2010;9(1):48.
4. Hapner ER, Wise JC. Results of a large-scale head and neck cancer screening of an at-risk population. *Journal of Voice.* 2011;25(4):3-480.
5. Islami F, Tramacere I, Rota M, Bagnardi V, Fedirko V, Scotti L, et al. Alcohol drinking and laryngeal cancer: Overall and dose–risk relationship–A systematic review and meta-analysis. *Oral oncology.* 2010;46(11):10-802.
6. Milner DA. *Diagnostic Pathology: Infectious Diseases E-Book: Elsevier Health Sciences*; 2015.
7. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. *The lancet oncology.* 2010;11(8):781-9.
8. Li X, Gao L, Li H, Gao J, Yang Y, Zhou F, et al. Human papillomavirus infection and laryngeal cancer risk: a systematic review and meta-analysis. *The Journal of infectious diseases.* 2012;207(3):479-88.

9. Syrjänen S. Human papillomavirus (HPV) in head and neck cancer. *Journal of clinical virology*. 2005;32:59-66.
10. Torrente MC, Rodrigo JP, Haigentz M, Dikkers FG, Rinaldo A, Takes RP, et al. Human papillomavirus infections in laryngeal cancer. *Head & neck*. 2011;33(4):6-581.
11. Campisi G, Panzarella V, Giuliani M, Lajolo C, Di Fede O, Falaschini S, et al. Human papillomavirus: Its identikit and controversial role in oral oncogenesis, premalignant and malignant lesions. *International journal of oncology*. 2007;30(4):813-23.
12. Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. *Virology*. 2010;401(1):9-70.
13. Gungor A, Cincik H, Baloglu H, Cekin E, Dogru S, Dursun E. Human papillomavirus prevalence in laryngeal squamous cell carcinoma. *The Journal of Laryngology & Otology*. 2007;121(8):4-772.
14. Morshed K, Polz-Dacewicz M, Szymański M, Polz D. Short-fragment PCR assay for highly sensitive broad-spectrum detection of human papillomaviruses in laryngeal squamous cell carcinoma and normal mucosa: clinicopathological evaluation. *European Archives of Oto-Rhino-Laryngology*. 2008;265(1):89-96.
15. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. *International journal of cancer*. 2017;141(4):664-70.
16. Gama RR, Carvalho AL, Filho AL, Scorsato AP, López RVM, Rautava J, et al. Detection of human papillomavirus in laryngeal squamous cell carcinoma: Systematic review and meta-analysis. *The Laryngoscope*. 2016;126(4):885-93.
17. Isayeva T, Li Y, Maswahu D, Brandwein-Gensler M. Human papillomavirus in non-oropharyngeal head and neck cancers: a systematic literature review. *Head and neck pathology*. 2012;6(1):104-20.
18. Fusconi M, Campo F, Gallo A, Zambetti G, Martellucci S, Seccia A, et al. Laryngeal cancer, HPV DNA vs E6/E7 mRNA test: a systematic review. *Journal of Voice*. 2017;31(2):248. e1-. e5.
19. Chernock RD, Wang X, Gao G, Lewis Jr JS, Zhang Q, Thorstad WL, et al. Detection and significance of human papillomavirus, CDKN2A (p16) and CDKN1A (p21) expression in squamous cell carcinoma of the larynx. *Modern Pathology*. 2013;26(2):223.
20. Schache AG, Liloglou T, Risk JM, Filia A, Jones TM, Sheard J, et al. Evaluation of human papillomavirus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination. *Clinical Cancer Research*. 2011;17(19):6262-71.
21. Jiron J, Sethi S, Ali-Fehmi R, Franceschi S, Struijk L, van Doorn LJ, et al. Racial disparities in human papillomavirus (HPV) associated head and neck cancer. *American journal of otolaryngology*. 2014;35(2):147-53.
22. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. *Cancer Epidemiology and Prevention Biomarkers*. 2005;14(2):467-75.
23. Kimple RJ, Smith MA, Blitzer GC, Torres AD, Martin JA, Yang RZ, et al. Enhanced radiation sensitivity in HPV-positive head and neck cancer. *Cancer research*. 2013.
24. Chen AM, Li J, Beckett LA, Zara T, Farwell G, Lau DH, et al. Differential response rates to irradiation among patients with human papillomavirus positive and negative oropharyngeal cancer. *The Laryngoscope*. 2013;123(1):152-7.
25. Megwalu UC, Sikora AG. Survival outcomes in advanced laryngeal cancer. *JAMA Otolaryngology–Head & Neck Surgery*. 2014;140(9):855-60.
26. Nowińska K, Ciesielska U, Podhorska-Okołów M, Dzięgiel P. The role of human papillomavirus in oncogenic transformation and its contribution to the etiology of precancerous lesions and cancer of the larynx: A review. *Advances in clinical and experimental medicine: official organ of Wrocław Medical University*. 2017;26(3):539-47.
27. Tong F, Geng J, Yan B, Lou H, Chen X, Duan C, et al. Prevalence and Prognostic Significance of HPV in Laryngeal Squamous Cell Carcinoma in Northeast China. *Cellular Physiology and Biochemistry*. 2018;49(1):206-16.
28. Akhondnezhad M, Haghshenas MR, Ghasemi M, Mousavi T. The prevalence and genotyping of human papillomavirus in patients with oral tumors in health centers and clinics of Mazandaran in Iran. *virus disease*. 2018;29(3):297-302.
29. Sánchez Barrueco A, González Galán F, Lora Pablos D, Villacampa Aubá JM, Ballestín Carcavilla C, Cenjor Español C, et al. HPV in Larynx Squamous Cell Carcinoma: New Serotypes and Survival Study within 10-Year Follow-up. *Otolaryngology–Head and Neck Surgery*. 2017;156(4):677-82.
30. Sekke TR, Burt FJ, Goedhals D, Goedhals J, Munsamy Y, Seedat RY. Human Papillomavirus in Head and Neck Squamous Cell Carcinomas in a South African Cohort. *Papillomavirus Research*. 2018.
31. Stedman TL. *Stedman's medical dictionary*. 1949.